{
    "nctId": "NCT00080626",
    "briefTitle": "Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer",
    "officialTitle": "A Pilot Study Assessing Patterns of Response or Resistance to Preoperative Dose Dense Docetaxel in Women With Newly Diagnosed Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 19,
    "primaryOutcomeMeasure": "Correlation between change in apoptosis and proliferation with response after definitive surgery",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed infiltrating carcinoma of the breast\n\n  * Unresected clinical stage T1c, T2, T3, or T4 lesion, any N\n* Newly diagnosed disease\n\n  * Diagnostic mammogram and an ultrasound of the affected breast within 3 months before study entry\n  * Mammogram of the contralateral breast within 6 months before study entry\n* Clinically measurable disease\n* Hormone receptor status:\n\n  * Immunohistochemical staining for estrogen and progesterone and HER2/neu receptors must be obtained on initial diagnostic material\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Hemoglobin at least 8 g/dL\n\nHepatic\n\n* Bilirubin no greater than 1.5 times normal\n\nRenal\n\n* Creatinine no greater than 1.5 times normal\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No medical condition that would put the patient at unnecessary risk of potentially serious complications during study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* No prior chemotherapy for current breast cancer\n\nEndocrine therapy\n\n* At least 1 month since prior tamoxifen or raloxifene for breast cancer prevention\n* No prior endocrine therapy for current breast cancer\n\nRadiotherapy\n\n* No prior radiotherapy for current breast cancer\n\nSurgery\n\n* Not specified",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}